Valneva reports positive initial phase 3 safety data in adolescents for its single-shot chikungunya vaccine candidate

Saint- herb lain (france ) , august 28 , 2 02 3 – valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company, today reported positive initial phase 3 safety data in adolescents for its single-dose chikungunya virus (chikv) vaccine candidate vla1553. immunogenicity data for the trial are expected in november 2023.
VALN Ratings Summary
VALN Quant Ranking